These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32184665)

  • 1. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
    He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
    Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases.
    Polivka J; Windrichova J; Pesta M; Houfkova K; Rezackova H; Macanova T; Vycital O; Kucera R; Slouka D; Topolcan O
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review.
    Schraa SJ; van Rooijen KL; Koopman M; Vink GR; Fijneman RJA
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Dec; 10(24):8820-8828. PubMed ID: 34821068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
    Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
    PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
    van 't Erve I; Medina JE; Leal A; Papp E; Phallen J; Adleff V; Chiao EJ; Arun AS; Bolhuis K; Simmons JK; Karandikar A; Valkenburg KC; Sausen M; Angiuoli SV; Scharpf RB; Punt CJA; Meijer GA; Velculescu VE; Fijneman RJA
    Clin Cancer Res; 2023 Mar; 29(5):899-909. PubMed ID: 36534496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
    Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
    Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
    Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
    Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
    Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management.
    Hallermayr A; Steinke-Lange V; Vogelsang H; Rentsch M; de Wit M; Haberl C; Holinski-Feder E; Pickl JMA
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.